A cross-sectional seroepidemiology study of EV-D68 in China

Sun, Shiqi; Gao, Fan; Hu, Yalin; Bian, Lianlian; Wu, Xing; Su, Yao; Du, Ruixiao; Fu, Ying Hui; Zhu, Fengcai; Mao, Qunying; Liang, Zhenglun

doi:10.1038/s41426-018-0103-4

Cited by 25 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EV-D68 seroprevalence rate was approximately 59% among children younger than 15 years old in China, and it was positively correlated with age among 1-year-old (10%) to 15-year-old (92%) children [18]. The seroprevalence rates of adults approach 100% in China, the United States, the United Kingdom, the Netherlands and Taiwan [10][11][12][13]18]. We thus listed and compared EV-D68 serostatus among different countries in Table 3.…”

Section: Plos Onementioning

confidence: 99%

“…The above finding could imply that EV-D68 has spread extensively worldwide, although only a limited number of severe cases have been reported. The cutoff for EV-D68 seropositivity was �1:8 [12,13,18], except in the UK study, which used a titer of >1:16 as the cutoff [12]. � The name or genotype of the viral strain was used for neutralizing antibody, and reverse genetics with Fermon strain was used to produce the EV-D68 virus (Synthetic) in the China study.…”

Section: Plos Onementioning

confidence: 99%

See 1 more Smart Citation

Enterovirus D68 seroepidemiology in Taiwan, a cross sectional study from 2017

et al. 2020

View full text Add to dashboard Cite

Background Enterovirus D68 (EV-D68) was discovered in 1962 and has unique characteristics compared to the characteristics of other enteroviruses. There were few documented cases before the epidemic in the United States in 2014. The Taiwan Centers for Diseases Control also confirmed that EV-D68 has been endemic, and some cases of acute flaccid myelitis were reported in Taiwan. To understand the current EV-D68 serostatus, we performed an EV-D68 seroepidemiology study in Taiwan in 2017. Methods After informed consent was obtained, we enrolled preschool children, 6-to 15-year-old students and 16-to 49-year-old people. The participants underwent a questionnaire investigation and blood sampling to measure the EV-D68 neutralization antibody. Results In total, 920 subjects were enrolled from the northern, central, southern and eastern parts of Taiwan with a male-to-female ratio of 1.03. The EV-D68 seropositive rate was 32% (26/82) in infants, 18% (27/153) in 1-year-old children, 43% (36/83) in 2-year-old children, 60% (94/ 156) in 3-to 5-year-old children, 89% (108/122) in 6-to 11-year-old primary school students, 98% (118/121) in 12-to 15-year-old high school students, 100% (122/122) in 16-to 49-yearold women and 100% (81/81) in 16-to 49-year-old males in 2017. Among preschool children, EV-D68 seropositivity was related to age (p for trend <0.0001), size of household ≧4 members (p = 0.037) and kindergarten attendance (p = 0.027). The seropositive rate varied among different geographic regions. Conclusion EV-D68 infection was prevalent, and its seropositive rates increased with age, larger household size and kindergarten attendance among preschool children.

show abstract

Section: Plos Onementioning

confidence: 99%

Section: Plos Onementioning

confidence: 99%

Enterovirus D68 seroepidemiology in Taiwan, a cross sectional study from 2017

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Evidence for continuous antigenic evolution. Given that most EV-D68 cases are pediatric (Holm-Hansen et al, 2016) and that almost everyone has high EV-D68 titers by the age of ten Karelehto et al, 2019;Sun et al, 2018;Xiang et al, 2017), one might expect that selection for antigenic change is of minor importance for the molecular evolution of EV-D68. However, we found rapid evolution in putative neutralizing epitopes, including the previously studied BC-and DE-loops (Du et al, 2015;Dyrdak et al, 2019).…”

Section: Bc-loopmentioning

confidence: 99%

“…The great majority of reported EV-D68 cases are pediatric (Holm-Hansen et al, 2016), and sero-positivity to EV-D68 increases rapidly during childhood, reaching ubiquity in adults Karelehto et al, 2019;Sun et al, 2018;Xiang et al, 2017). Relatively little is known about immunity to EV-D68, but infection appears to elicit long-lasting strain-specific immunity, as evidenced by the high prevalence among adults of neutralising antibodies to the prototype Fermon strain from 1962 Karelehto et al, 2019;Smura et al, 2010;Xiang et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Evolution, geographic spreading, and demographic distribution of Enterovirus D68

Hodcroft

Dyrdak

Andrés

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundWorldwide outbreaks of enterovirus D68 (EV-D68) in 2014 and 2016 have caused serious respiratory and neurological disease.MethodsWe collected samples from several European countries during the 2018 out-break and determined 53 near full-length genome (‘whole genome’) sequences. These sequences were combined with 718 whole genome and 1,987 VP1-gene publicly available sequences.FindingsIn 2018, circulating strains clustered into multiple subgroups in the B3 and A2 subclades, with different phylogenetic origins. Clusters in subclade B3 emerged from strains circulating primarily in the US and Europe in 2016, though some had deeper roots linking to Asian strains, while clusters in A2 traced back to strains detected in East Asia in 2015-2016. In 2018, all sequences from the USA formed a distinct subgroup, containing only three non-US samples. Alongside the varied origins of seasonal strains, we found that diversification of these variants begins up to 18 months prior to the first diagnostic detection during a EV-D68 season. EV-D68 displays strong signs of continuous antigenic evolution and all 2018 A2 strains had novel patterns in the putative neutralizing epitopes in the BC- and DE-loops. The pattern in the BC-loop of the USA B3 subgroup had not been detected on that continent before. Patients with EV-D68 in subclade A2 were significantly older than patients with a B3 subclade virus. In contrast to other subclades, the age distribution of A2 is distinctly bimodal and was found primarily among children and in the elderly.InterpretationWe hypothesize that EV-D68’s rapid evolution of surface proteins, extensive diversity, and high rate of geographic mixing could be explained by substantial reinfection of adults.FundingUniversity of Basel and Swedish Foundation for Research and Development in Medical Microbiology

show abstract

“…The EV-D68 seroprevalence rate is around 59% in China and anti-EV68 neutralizing antibodies titer increase with time according to previous reports. 34,35 Another 2014 study that included 319 participants aged between six to 35 months old in Jiangsu, China found that the seropositive rate increased from 49.2% in 2012 to 60.5%. 36 Adults are widely infected with EV-D68 and have higher seroprevalence rates.…”

Section: Seroprevalencementioning

confidence: 99%

Current status of enterovirus D68 worldwide and in Taiwan

Chang

2020

Pediatrics & Neonatology

View full text Add to dashboard Cite

Enterovirus D68 was first identified in 1962 and caused a worldwide outbreak starting from the North America in 2014. Enterovirus D68 has been in continuous circulation among many countries recently, including Taiwan. Reports also reveal high seroprevalence, which indicates that the disease burden of enterovirus D68 may be underestimated via viral culture or polymerase chain reaction results. Although most infected cases have mild respiratory illness, severe complications including acute flaccid myelitis and acute respiratory distress syndrome have also been reported. In the position of an emerging pathogen, enterovirus D68 poses a threat to public health and may cause devastating diseases. Diverse severity of neurological sequelae remains inevitable among acute flaccid myelitis patients, but no curable treatment is available currently. According to the management suggestions of the American Centers of Disease Control, uses of corticosteroids and plasmapheresis are either preferred or avoided and intravenous immunoglobulin also has no clear indication in the treatment for acute flaccid myelitis. In this review article, we provide information about the epidemiology, clinical recognition and treatment strategy of enterovirus D68. Better understanding of this disease is the foothold for advanced investigation and monitoring in the future.

show abstract

A cross-sectional seroepidemiology study of EV-D68 in China

Cited by 25 publications

References 26 publications

Enterovirus D68 seroepidemiology in Taiwan, a cross sectional study from 2017

Enterovirus D68 seroepidemiology in Taiwan, a cross sectional study from 2017

Evolution, geographic spreading, and demographic distribution of Enterovirus D68

Current status of enterovirus D68 worldwide and in Taiwan

Contact Info

Product

Resources

About